Wells Fargo & Company Issues Positive Forecast for Integer (NYSE:ITGR) Stock Price

Integer (NYSE:ITGR) had its target price increased by analysts at Wells Fargo & Company from $84.00 to $127.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective indicates a potential upside of 2.05% from the company’s previous close.

Several other research firms have also issued reports on ITGR. Freedom Capital upgraded Integer to a “strong-buy” rating in a report on Wednesday, July 22nd. Citigroup boosted their price target on Integer from $92.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Zacks Research upgraded Integer from a “strong sell” rating to a “hold” rating in a research note on Monday, July 20th. Raymond James Financial downgraded Integer from a “moderate buy” rating to a “hold” rating in a report on Monday. Finally, HC Wainwright restated a “buy” rating on shares of Integer in a report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $109.86.

Integer Stock Up 2.7%

Shares of ITGR stock opened at $124.44 on Tuesday. The firm’s fifty day moving average price is $94.58 and its two-hundred day moving average price is $89.28. The company has a current ratio of 3.75, a quick ratio of 2.38 and a debt-to-equity ratio of 0.77. Integer has a 1 year low of $62.00 and a 1 year high of $125.54. The firm has a market capitalization of $4.23 billion, a P/E ratio of 31.03, a PEG ratio of 2.89 and a beta of 0.61.

Integer (NYSE:ITGR) last posted its quarterly earnings data on Monday, August 3rd. The medical equipment provider reported $1.60 EPS for the quarter, topping analysts’ consensus estimates of $1.38 by $0.22. The company had revenue of $464.11 million during the quarter, compared to the consensus estimate of $450.67 million. Integer had a net margin of 7.64% and a return on equity of 12.83%. The company’s quarterly revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.55 EPS. On average, equities analysts predict that Integer will post 6.04 EPS for the current fiscal year.

Institutional Trading of Integer

Several hedge funds and other institutional investors have recently bought and sold shares of ITGR. Salomon & Ludwin LLC boosted its holdings in Integer by 46.8% in the 4th quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 118 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Integer by 48.1% during the first quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 117 shares during the period. TD Private Client Wealth LLC increased its holdings in shares of Integer by 1,037.5% during the fourth quarter. TD Private Client Wealth LLC now owns 455 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 415 shares during the period. Parkside Financial Bank & Trust raised its position in shares of Integer by 135.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 267 shares in the last quarter. Finally, Arax Advisory Partners raised its position in shares of Integer by 2,489.5% in the fourth quarter. Arax Advisory Partners now owns 492 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 473 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

More Integer News

Here are the key news stories impacting Integer this week:

• Positive Sentiment: KKR agreed to acquire Integer for approximately $5.7 billion, or $127 per share in cash. The offer represents a 51.8% premium to the April 29 price before Integer disclosed its strategic review and provides shareholders with a defined cash exit. The transaction is expected to close by year-end 2026, subject to shareholder and regulatory approvals. Integer to Be Acquired by KKR
• Positive Sentiment: Second-quarter earnings per share were $1.60, exceeding the $1.38 analyst consensus, while revenue of $464.1 million topped estimates of $450.7 million. EPS also improved from $1.55 in the year-ago quarter, supporting the case for operational strength. Integer Q2 Earnings and Revenues Top Estimates
• Neutral Sentiment: KKR says it plans to provide capital for Integer’s capacity, technology, innovation and talent investments, and intends to establish an employee ownership program after closing. However, Integer will withdraw its financial outlook and cancel its scheduled earnings call because of the pending transaction, reducing near-term visibility for public-market investors. Integer KKR Transaction Details
• Negative Sentiment: Truist Financial downgraded Integer from “strong buy” to “hold,” likely reflecting the stock’s proximity to the $127 acquisition price and limited remaining upside. Integer Analyst Downgrade
• Negative Sentiment: Several law firms announced investigations into whether Integer’s board obtained a fair price or breached fiduciary duties in connection with the KKR sale. These announcements could create litigation, delay or transaction-completion risks, although they do not by themselves indicate that the deal will fail. Integer Shareholder Investigation

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.